Summary
Becton, Dickinson and Company (BDX) filed an 8-K on April 27, 2005, to report its second fiscal quarter financial results for fiscal year 2005. The filing primarily serves to furnish a press release detailing these results, which includes the company's use of non-GAAP financial measures to provide investors with a clearer view of its underlying operational performance. These non-GAAP adjustments aim to exclude the impact of foreign currency fluctuations, significant charges, share-based compensation expense, and changes in tax laws to enhance comparability with prior periods. Additionally, the report discloses two significant legal events. Firstly, a qui tam action against BDX under the Federal False Claims Act was dismissed without prejudice on April 15, 2005. Secondly, on April 21, 2005, Dynovation Medical, Inc. filed a lawsuit against BDX alleging breach of a license agreement and patent infringement related to the Insyte Autoguard IVTM catheter product. BDX maintains these allegations are without merit and intends to defend itself vigorously.
Key Highlights
- 1BDX furnished its Q2 FY2005 financial results via press release filed as Exhibit 99.1.
- 2The company utilizes non-GAAP financial measures, including constant foreign exchange rates, to present performance.
- 3Non-GAAP adjustments exclude significant charges, share-based compensation, and tax law changes for better period-to-period comparability.
- 4BDX management uses these non-GAAP measures for performance evaluation and budget planning.
- 5A qui tam action against BDX under the Federal False Claims Act was dismissed without prejudice on April 15, 2005.
- 6Dynovation Medical, Inc. filed a lawsuit on April 21, 2005, alleging breach of contract and patent infringement related to a catheter product.
- 7BDX believes the Dynovation lawsuit allegations are without merit and intends to defend itself vigorously.